Immupharma Share Discussion Threads

[rb1206] 05/12/2017 11:54

NY Boy: Thx. When move happen it will be fast just like VRS and PYC last week.

[obiterdicta] 05/12/2017 11:49

Flavio - Good question -probably £2 million. So would need £30.00 per share as have other investments.

OD

[flavio_monteiro] 05/12/2017 11:47

obiterdicta ---Depends on how much you need to retire!

[obiterdicta] 05/12/2017 11:41

New York Boy - is 50k shares a reasonable amount?

[ny boy] 05/12/2017 11:37

Usual mugging of weak holders, rinse & repeat, you would of think some would have learnt the lesson!🙄

Most of the weak sellers are just buying on credit, so MM’s know the time to hit them.

Just buy the stock, as much as you can afford, pay for the stock and tuck away for a cold winter but by Spring the daffodils etc will be out in the sunshine. Either that go abroad, don’t check the share price until Spring..then retire if you have bought a reasonable amount. GL all long term holders.

[top tips] 05/12/2017 11:01

Cheeky little top up. Looking good for another progress announcement this month.

[money maker1] 05/12/2017 10:32

£60 to £100.

[ny boy] 05/12/2017 10:16

Being held back until we clear the block of sellers between 130.75p - 135p about 125000 of sells lined up, after those have been hoovered up this week, should get a move into 140p’s

[rb1206] 05/12/2017 09:59

At the moment 130 is resistance, previous all time high @ 136 (intraday 144) in Nov 2009 hence last few days ppl selling around here, but its refusing to go lower and consolidating before next b/o. Once pass through here, its open blue sky........imho

[che7win] 05/12/2017 08:57

IMM poking its head above 130p - thats new territory and very bullish IMHO.

Next leg up may be imminent.

[ny boy] 05/12/2017 08:56

Agree, same pattern as before consolidation before another breakout, tick tock.

Potentially a huge pot of £££;£, ready to collect next Spring.

[lodgeview] 05/12/2017 08:24

On the cusp of a breakout too. Not a lot to dislike about being in here!

[lodgeview] 05/12/2017 08:21

Just bought 7640 shares but not shown up yet. Watched the ii interview from earlier this year. We are in Phase3 and it appears that this could be huge. Worldwide blockbuster drug with no side effects!

[top tips] 05/12/2017 08:03

Wllmherk the more value here the better as far as most shareholders would be concerned. Few pharmas, including large pharmas, have anything as potentially valuable as Lupuzor P140.

[hamila01] 05/12/2017 07:14

wllmherk - and this is an AIM share too!!!

[barneygumble27] 05/12/2017 07:06

In here and valirx both starting to look good

[wllmherk] 05/12/2017 07:06

ballsac et al, you are making me nervous with all these wild predictions, in my experience when people start getting carried away they end up looking foolish.
Anyway, if results are good a big Pharma wont offer the kind of figures being bandied about, why would they ? shareholders will sell out for much much less than £100 per share,

wllm

[ballsac] 04/12/2017 23:52

I told you this would be worth a fortune.

[asat91] 04/12/2017 22:46

An article (written by a professor of medicine and chief of Rheumatology) for those interested in the SLEDAI-2K which is being used in the lupuzor phase III trial to measure disease severity:



Also interesting to note that Benlysta failed to meet either of it's primary endpoints for it's phase 2 trial, but was progressed due to post-hoc analysis showing some 'promising signs' and secondary endpoints being met. This indicates to me how desperate the FDA are for new lupus drugs IMO. A drug that failed it's phase II trial was still approved.

I can imagine a situation where lupuzor fails to meet it's primary endpoints but still achieves FDA approval based on 'promising signs' in the secondary endpoints in combination with the outstanding safety profile

[davr0s] 04/12/2017 18:30

No shares for sale until 150p - lol

[jpleight] 04/12/2017 18:29

are we there yet? how was level 2 looking today?

[hottingup] 04/12/2017 18:15

asat91,

Good places to start are IMM's updated website and a Lupuzor Symposium last year:



A shift in treating auto-immune disease

"This targeted approach marks a paradigm shift in treating autoimmune disease. Instead of shutting down otherwise healthy immune responses the T-cells are suppressed leaving the immune system modified but intact."

Autophagy represents a key pathway

"Autophagy represents a key pathway that is targeted by the P140/Lupuzor™ peptide. Defects in this complex process underlie many types of diseases, including autoimmune, many inflammatory diseases, and degenerative neurological illnesses (e.g. Parkinson’s and Alzheimer’s diseases), and aging. Thus, therapeutic agents such as P140/Lupuzor™, are unique molecules that may significantly slow down or correct the course of such diseases and considerably improve the quality of the life of patients."



Forigerimod/PI40 targeting major auto-immune disease indications

"ImmuPharma together with Professor Sylviane Muller, Lupuzor’s inventor, have presented new evidence supporting Lupuzor’s™ Forigerimod / P140 peptide activity in several other major auto-immune disease indications outside of Lupus including Rheumatoid Arthritis, Crohn’s Disease, and Asthma. In particular, the peptide appears to have general effects against chronic inflammatory indications. Other pre-clinical evidence supports the molecule’s use in: Neuropsychiatric lupus (NPSLE); Gougerot-Sjögren syndrome (GSS); and Guillain-Barre disease (chronic/CIDP)."

Lupuzor™ Symposium
8th June 2016 - 3:35 pm

41 min 40 sec onwards -


Indications with promising clinical or preclinical data:
- Systemic Lupus Erythematosus (SLE) (Market size $4 bn) (SLE ends Phase 3, Q1 2018)
- Neuropsychiatric lupus (NPSLE)
- Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024)
- Rheumatoid Arthritis (Market size $28.5 bn by 2025)
- Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024)
- Crohn's Disease + Ulcerative Colitis (Market size $4 bn by 2022)
- Guillan-Barre disease
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Asthma (Market size $20.7 bn in 2015)

Other potential evaluations:
- Scleroderma (Systemic Sclerosis, Raynaud)
- Psoriasis
- Multiple Sclerosis (MS) (Market size $20 bn by 2024)
- (Others to follow)

Negative preclinical results for potential re-evaluation:
- Type I Diabetes (Market size $43 bn by 2021)
- Amytrophic Lateral Sclerosis (ALS)

P.S.
Systemic Lupus Erythematosus (SLE) ends of Phase 3, Q1 2018.

[asat91] 04/12/2017 16:39

Hottingup can you provide a link with the early evidence that suggests P140 could be used in ALL of those diseases?

[hottingup] 04/12/2017 15:44

On the basis we assume Lupuzor passes Phase 3 in Q1 2018 then any valuation of Lupuzor / P140 must start as a minimum with the $3.6 billion paid in 2012 by GSK to acquire HGSi's 50% stake in lupus drug Benlysta - effectively valuing 100% of Benlysta at $7 billion - equating to an IMM share price around £40.

To that $7 billion (£40) should then be added something for inflation during what in 2018 will then be the last 6 years since 2012; Lupuzor (I assume) being more efficaceous, having less or no side effects, being cheaper to produce and more comfortable to administer, than Benlysta; use in other multiple indications (including off label and on label) some of which have market sizes many times larger than for lupus; new patent granted to 2032 in key countries (USA, EU, China, India and Japan) covering Lupuzor and its use in the treatment of the majority of autoimmune diseases such as Sjogrens syndrome, rheumatoid arthritis, Crohn's, CIDP, Guillan-Barre disease (announced 27/9/2017); and a new patent recently filed (2017) to cover non-autoimmune indications.

Consequently the value of Lupuzor in Q1 2018 should be much higher than $7 billion (potentially multiples) and the share price much higher than £40.

N.B.
Lupuzor™ Symposium
8th June 2016 - 3:35 pm

41 min 40 sec onwards -


Data from IMM suggests Lupuzor / P140 may be able to treat several blockbuster autoimmune and non-autoimmune diseases, including:

- Systemic Lupus Erythematosus (SLE) (Market size $4 bn) (SLE ends Phase 3, Q1 2018)
- Neuropsychiatric lupus (NPSLE)
- Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024)
- Rheumatoid Arthritis (Market size $28.5 bn by 2025)
- Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024)
- Crohn's Disease + Ulcerative Colitis (Market size $4 bn by 2022)
- Guillan-Barre disease
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Asthma (Market size $20.7 bn in 2015)

Other potential evaluations:
- Scleroderma (Systemic Sclerosis, Raynaud)
- Psoriasis
- Multiple Sclerosis (MS) (Market size $20 bn by 2024)

Negative preclinical results for potential re-evaluation:
- Type I Diabetes (Market size $43 bn by 2021)
- Amytrophic Lateral Sclerosis (ALS)